- Company
- K-Bio in ASCO 2020: Seeking the optimal combination
- by Choi sun May 27, 2020 06:07am
- From May 29, ten of Korean pharmaceutical and bio companies are to participate in the virtually held American Society of Clinical Oncology Annual Meeting (ASCO) 2020. GC Pharma, SillaJen, Genexine and many other Korean companies are planning to present various clinical study outcomes related to anticancer treatments. The ASCO annual
- Company
- KRPIA-MOHW meeting rescheduled on May 28
- by Eo, Yun-Ho May 27, 2020 06:05am
- Korean Research-based Pharmaceutical Industry Association (KRPIA) and Ministry of Health and Welfare (MOHW) have rescheduled their meeting canceled last week due to a confirmed case of COVID-19. According to a pharmaceutical industry source, a meeting between MOHW Pharmaceutical Benefits Division and KRPIA Market Access (MA) and Governme
- Company
- Prevenar13 by Pfizer sales increased 50%
- by An, Kyung-Jin May 26, 2020 06:05am
- Pfizer's pneumococcal vaccine 'Prevenar 13' had a high sales. It is evaluated that reflex profits appeared as anticipation for the effect of preventing pneumonia increased due to prolongation of COVID-19 outbreak. According to the drug research agency IQVIA on the 21st, 'Prevenar 13' sales in the first quarter increased 52.2% to &8361;17.
- Company
- Improving access to Lenvima and its later-line treatment
- by Eo, Yun-Ho May 25, 2020 06:27am
- 1 The Korean pharmaceutical industry is keeping a close eye on the Cancer Deliberation Committee’s June meeting to discuss the coverage on later-line treatment following Lenvima treating liver cancer. The pharmaceutical industry sources reported the Cancer Deliberation Committee could talk about extending the access of patient with hepatoce
- Company
- Erectile dysfunction treatment market suffered from COVID-19
- by An, Kyung-Jin May 25, 2020 06:26am
- The well-established domestic erectile dysfunction treatment market was stagnant. As the sales of large products sold by Hanmi Pharm, Chong Kun Dang, and Pfizer decreased, the overall market size was lowered. According to the analysis, the market for erectile dysfunction treatment, which has a relatively low disease severity, has been suff
- Company
- Pfizer stopped Duavive due to quality problems
- by Kim, Jin-Gu May 25, 2020 06:26am
- Pfizer Pharmaceuticals voluntarily recovers its own menopausal treatment drug Duavive. This is based on the identification of potential quality problems in the results of self-investigation. On the 21st, Pfizer Pharmaceuticals requested each drug distributor to discontinue certain lot numbers of Duavive 0.45mg / 20mg folowing as ▲DC5278
- Company
- Alvogen Korea secures domestic rights for Seroquel
- by An, Kyung-Jin May 25, 2020 06:26am
- Alvogen Korea took over the domestic rights of the drug 'Seroquel' (Quetiapine), a treatment for schizophrenia. Alvogen Korea announced on the 21st that it has signed an exclusive distribution and marketing contract for 'Seroquel' and 'Seroquel XR' with Luye Pharma in China, and approval of the domestic license has been completed. Seroq
- Company
- Qsymia puts a brake on Saxenda in Q1 obesity drug market
- by An, Kyung-Jin May 22, 2020 06:17am
- The Korean obesity treatment market has fluctuated significantly in the year. The so-called ‘Gangnam Diet Injection,’ Saxenda lost its solid market leadership and now shares the top spot with Qsymia. Saxenda’s sales has halved as soon as Qsymia entered the market and took over a significant part of it. On May 20, pharmaceutical marke
- Company
- MOHW-KRPIA meeting canceled as confirmed COVID-19 reported
- by Eo, Yun-Ho May 22, 2020 06:16am
- A confirmed case of COVID-19 was reported from Twin City Namsan building that houses the office of Korean Research-based Pharmaceutical Industry Association (KRPIA). Accordingly, the meeting originally scheduled on May 21 to convene Ministry of Health and Welfare (MOHW) Division of Pharmaceutical Benefits officials and KRPIA and multinat
- Company
- Promising shingles vaccine market halved by COVID-19
- by Chon, Seung-Hyun May 21, 2020 06:01am
- The Korean shingles prevention vaccine market has halved this year. SK Bioscience' Sky Zoster has been maintaining high growth since its launch in 2018, but the market itself plummeted recently due to the COVID-19 outbreak. According to pharmaceutical market research firm IQVIA, this year’s first quarter shingles vaccine market marked
